Biomedical research is at risk of losing the antibiotics vs. pathogens arms race. Pneumonia, tuberculosis, gonorrhea, and salmonellosis are becoming harder and sometimes impossible to treat due to the fast emergence and global spread of new antibiotic resistance. Without urgent action, we are heading for a post-antibiotic era, in which common infections and minor injuries …
Category Archive: multidrug resistance
Feb 14
Center for the Translational Sciences Indiana Awards us Seed Grant for an Innovative Antibiotic Free Nanotherapeutics to Combat Multi-drug Resistant Bacterial Infections
Categories:
AD&T Notre Dame, antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Grants funding, multidrug resistance
by Prakash
Tags: NDNano
Recent Posts
- Nallathamby Lab’s Kevin Armknecht is Invited to Present at the Midwest Microscopy and Microanalysis Workshop 2024 May 7, 2024
- 7th Annual End of Spring Nallathamby Group Dinner – May 3rd, 2024 May 3, 2024
- SOFWERX – Genomic Non-Specific Operational Matchmaking Enabled Systems April 23, 2024
- Harper Cancer Research Institute Research Day – April 15, 2024 April 15, 2024
- Kevin Armknecht of the Nallathamby Lab is the First Undergraduate to Win the Notre Dame Integrated Imaging Facility Award in Recognizing Imaging Excellence Through Publication for 2023 March 20, 2024
Archives
Categories
NIH Funding Opportunities
- STTR Solutions to Enable Population Genomic Screening (R41/R42 Clinical Trial Optional) August 16, 2024Funding Opportunity PAR-24-262 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit Small Business Technology Transfer (STTR) grant applications from small businesses to develop innovative solutions for commercialization that would enable population screening for common, actionable genomic conditions in a primary care setting.
- Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed) August 16, 2024Funding Opportunity RFA-HD-25-003 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the Pediatric HIV/AIDS Cohort Study (PHACS) as a transformative and agile program addressingthe developmental and clinical course of persons living with HIV, and vertically acquired HIV, with an emphasis on youth through reproductive age.
- Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) August 16, 2024Notice NOT-NS-24-015 from the NIH Guide for Grants and Contracts
- Notice of NHLBI Participation in RFA-AT-24-010 "Whole Person Research and Coordination Center (Whole Person RCC) U24 (Clinical Trial Not Allowed)" August 16, 2024Notice NOT-HL-24-022 from the NIH Guide for Grants and Contracts
- Single Source for the Continuation of the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional) August 16, 2024Funding Opportunity RFA-DK-25-018 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type […]
- Limited Competition for the Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers (T1DAPC-CCs) (U01 Clinical Trial Optional) August 16, 2024Funding Opportunity RFA-DK-25-017 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), […]
- SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional) August 16, 2024Funding Opportunity PAR-24-263 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit Small Business Innovation Research (SBIR) grant applications from small businesses to develop innovative solutions for commercialization that would enable population screening for common, actionable genomic conditions in a primary care setting.
- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R21 Clinical Trials Not Allowed) August 15, 2024Funding Opportunity RFA-DA-26-008 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address […]
- Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed) August 15, 2024Funding Opportunity RFA-DA-26-007 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support studies to delineate the mechanisms by which sex hormones influence the consequences of comorbid HIV and drug use and use this knowledge to explore biological mechanisms as potential therapeutic targets to address […]
- Notice of Informational Webinar for Cancer Prevention Clinical Trials Network (CP-CTNet): RFA-CA-24-024 and RFA-CA-24-025 August 15, 2024Notice NOT-CA-24-095 from the NIH Guide for Grants and Contracts
Recent Comments